SurModics Inc. (SRDX:NASD)の戦略的SWOT分析（2026年6月）

Report Overview

Report Summary

SurModics Inc. Strategic SWOT Insights – A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends Report is a comprehensive and easily accessible overview of SurModics Inc. ‘s business operations. It provides a detailed analysis of the company’s strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company’s performance.

The report begins with in-depth information about SurModics Inc. including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company’s key attributes.

Next, the report assesses SurModics Inc.’s strategic standing through various analyses. The ESG spotlight evaluates the company’s environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company’s internal strengths and weaknesses, as well as external opportunities and threats. By integrating these strategic analyses, the report offers a comprehensive understanding of SurModics Inc.’s overall strategic standing and supports informed decision-making and strategic planning.

Finally, the report includes recent news and deal activities undertaken by SurModics Inc. enhancing awareness of the company’s business trends, growth perspectives, and more.

Key Highlights

Surmodics, Inc., founded in 1979, is a publicly traded medical device company headquartered at Eden Prairie, Minnesota, United States. The company has a strong global presence, including operations in Ireland at IDA Business Park, Ballinasloe, Co. Galway, supporting its international manufacturing and development capabilities. Surmodics specializes in advanced surface technologies and medical device solutions, with a focus on innovative coatings, contract development, and in vitro diagnostics. Its business segments include Interventional Medical Devices and In Vitro Diagnostics Components. The Medical Device segment develops and manufactures proprietary hydrophilic, hemocompatible, and drug-delivery coatings for vascular intervention devices, including products such as the SurVeil drug-coated balloon for peripheral arterial disease and the Pounce thrombectomy platform for thrombus removal. The In Vitro Diagnostics segment focuses on chemical and biological components for diagnostic immunoassays and molecular testing, including protein stabilizers and antigens. Surmodics leverages its expertise to support clients from concept through commercialization, serving as a critical partner in creating differentiated drug/device combination products.

SurModics Inc. in the News:-

2026-05-19 – Endologix Acquires PounceTM Thrombectomy System, Expanding Its Vascular Intervention Portfolio
2025-04-22 – Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil Drug-Coated Balloon
2025-04-03 – Surmodics Announces Commercial Release of Pounce XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries
2025-03-06 – Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
2025-02-03 – Surmodics Announces Successful Early Clinical Use of Pounce XL Thrombectomy System, Suitable for Non Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries

Scope

• Tactical Analysis:- Various strategic frameworks to gain insights into a company’s competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
• Business Strategy:- Contributes to shaping the company’s overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
• Company Fundamentals:- These fundamentals offer valuable insights into the company’s history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
• Competitive Landscape:- An identification of the company’s main competitors, providing insights into the competitive landscape it operates in.

Reasons to Buy

• Comprehensive Understanding of the SurModics Inc.’s internal and external factors through SWOT analysis and Corporate Strategy.
• Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
• Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
• Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
• Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company SurModics Inc.:

• SurModics Inc. PESTLE Analysis
• SurModics Inc. Value Chain Analysis
• SurModics Inc. Porter’s Five Forces Analysis
• SurModics Inc. VRIO Analysis
• SurModics Inc. BCG Analysis
• SurModics Inc. Segmentation, Targeting and Positioning (STP) Analysis
• SurModics Inc. Ansoff Matrix Analysis

Table of Contents

Tables 5
Charts 6
SurModics Inc. – Key Company Facts 7
SurModics Inc. – Company Description 8
SurModics Inc. – Top Executives 9
SurModics Inc. – Head Office & Locations 10
Head Office – Country 10
SurModics Inc. – Products and Services 11
Products 11
Services 12
SurModics Inc. – Corporate Strategy 13
SurModics Inc. – Business Description 16
Interventional Medical Devices 16
Medical Device Coatings and Surface Technologies 17
Contract Development and Manufacturing Services 18
In Vitro Diagnostics Components 19
SurModics Inc. – ESG Spotlight 20
Environment 20
Social 21
Corporate Governance 21
SurModics Inc. – SWOT Analysis 23
Overview 23
Strengths 25
Weaknesses 28
Opportunities 30
Threats 32
Competing Players 34
Snapshot of Competing Players 35
Boston Scientific Corporation 35
Key Company Facts 35
Company Description 35
Boston Scientific Corporation – SWOT Spotlight 36
Boston Scientific Corporation – PESTLE Spotlight 38
Key Financials 40
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 40
Key Financial Ratio Analysis 45
Medtronic plc 47
Key Company Facts 47
Company Description 47
Medtronic plc – SWOT Spotlight 48
Medtronic plc – PESTLE Spotlight 50
Key Financials 52
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 52
Key Financial Ratio Analysis 57
Covalon Technologies Ltd 59
Key Company Facts 59
Company Description 59
Key Financials 60
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 60
Key Financial Ratio Analysis 65
Key Financials 67
Share Price Trend – Jun-2025 to Jun-2026 (Average Share Closing Price) 67
Key Financial Ratio Analysis 72
SurModics Inc. – In the News 74
22-Apr-2025- Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil Drug-Coated Balloon 74
03-Apr-2025- Surmodics Announces Commercial Release of Pounce XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries 77
06-Mar-2025- Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR 79
03-Feb-2025- Surmodics Announces Successful Early Clinical Use of Pounce XL Thrombectomy System, Suitable for Non Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries 81
01-Oct-2024- Surmodics Receives FDA 510k Clearance for Pounce XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter 82
10-Jun-2024- Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc 83
SurModics Inc. – Key Deals 84
22-Jan-2024 – Surmodics Announces Successful Early Clinical Use of Pounce LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee 84
Appendix 86
Definitions 86
SWOT Analysis 86
PESTLE Analysis 86
Value Chain Analysis 86
ESG Spotlight 86
Research Methodology 87
Disclaimer 88
Contact Us 88

List of Tables

Table 1: SurModics Inc. – Company Facts 7
Table 2: SurModics Inc. – Digital Presence 7
Table 3: SurModics Inc. – Top Executives 9
Table 4: SurModics Inc. – Products 11
Table 5: SurModics Inc. – Services 12
Table 6: SurModics Inc. -Competing Players 34
Table 7: Competing Players – Boston Scientific Corporation – Key Company Facts 35
Table 8: Boston Scientific Corporation – Share Price Trend – Jun-2025 to Jun-2026 40
Table 9: Competing Players – Boston Scientific Corporation – Profit and Loss Statement 42
Table 10: Boston Scientific Corporation – Balance Sheet 2022-2025 43
Table 11: Boston Scientific Corporation – Cash Flow Statement 2022-2025 44
Table 12: Boston Scientific Corporation – Ratio Analysis – 2022-2025 45
Table 13: Competing Players – Medtronic plc – Key Company Facts 47
Table 14: Medtronic plc – Share Price Trend – Jun-2025 to Jun-2026 52
Table 15: Competing Players – Medtronic plc – Profit and Loss Statement 54
Table 16: Medtronic plc – Balance Sheet 2022-2025 55
Table 17: Medtronic plc – Cash Flow Statement 2023-2026 56
Table 18: Medtronic plc – Ratio Analysis – 2023-2026 57
Table 20: Competing Players – Covalon Technologies Ltd – Key Company Facts 59
Table 21: Covalon Technologies Ltd – Share Price Trend – Jun-2025 to Jun-2026 60
Table 22: Competing Players – Covalon Technologies Ltd – Profit and Loss Statement 62
Table 23: Covalon Technologies Ltd – Balance Sheet 2022-2025 63
Table 24: Covalon Technologies Ltd – Cash Flow Statement 2022-2025 64
Table 25: Covalon Technologies Ltd – Ratio Analysis – 2022-2025 65
Table 27: Sono-Tek Corp – Share Price Trend – Jun-2025 to Jun-2026 67
Table 28: Competing Players – Sono-Tek Corp – Profit and Loss Statement 69
Table 29: Sono-Tek Corp – Balance Sheet 2023-2026 70
Table 30: Sono-Tek Corp – Cash Flow Statement 2023-2026 71
Table 31: Sono-Tek Corp – Ratio Analysis – 2023-2026 72

List of Figures

Figure 1: SurModics Inc. – SWOT Analysis 24
Figure 2: Competing Players – Boston Scientific Corporation – SWOTSpotlight 37
Figure 3: Competing Players – Boston Scientific Corporation – PESTLE Spotlight 39
Figure 4: Boston Scientific Corporation – Average Share Price Trend -Jun-2025 to Jun-2026 41
Figure 5: Boston Scientific Corporation – Profit and Loss Statement – 2022-2025 42
Figure 6: Boston Scientific Corporation – Balance Sheet – 2022-2025 43
Figure 7: Boston Scientific Corporation – Cash Flow Statement 2022-2025 44
Figure 8: Competing Players – Medtronic plc – SWOTSpotlight 49
Figure 9: Competing Players – Medtronic plc – PESTLE Spotlight 51
Figure 10: Medtronic plc – Average Share Price Trend -Jun-2025 to Jun-2026 53
Figure 11: Medtronic plc – Profit and Loss Statement – 2023-2026 54
Figure 12: Medtronic plc – Balance Sheet – 2022-2025 55
Figure 13: Medtronic plc – Cash Flow Statement 2023-2026 56
Figure 14: Covalon Technologies Ltd – Average Share Price Trend -Jun-2025 to Jun-2026 61
Figure 15: Covalon Technologies Ltd – Profit and Loss Statement – 2022-2025 62
Figure 16: Covalon Technologies Ltd – Balance Sheet – 2022-2025 63
Figure 17: Covalon Technologies Ltd – Cash Flow Statement 2022-2025 64
Figure 18: Sono-Tek Corp – Average Share Price Trend -Jun-2025 to Jun-2026 68
Figure 19: Sono-Tek Corp – Profit and Loss Statement – 2023-2026 69
Figure 20: Sono-Tek Corp – Balance Sheet – 2023-2026 70
Figure 21: Sono-Tek Corp – Cash Flow Statement 2023-2026 71